lung, and other cancers in adults. For a doctor to prescribe Enhertu, the cancer must involve HER2 in some way. Each of these cancers also has other specific criteria for treatment with Enhertu ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and advanced HER2-positive solid tumours, which have driven sales to more than $3. ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan ... the DESTINY-Lung01 study in HER2-positive non-small cell lung cancer (NSCLC), including an overall response rate of 55% and ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

Interstitial lung disease or pneumonitis was reported in 11.3% of patients treated with ENHERTU, with most cases being low grade. Currently, ENHERTU is approved in over 75 countries for patients with ...